Close Menu

Diagnostics

News and analysis on diagnostic technologies and applications.

Lantern Pharma is using its RADR platform to repurpose two drugs currently in clinical trials and advance a new drug in preclinical testing.

The open-label, multi-center trial will start enrolling patients in the third quarter to evaluate the safety of lasofoxifene combined with abemaciclib.

The companies will work together to bring Guardant360 through regulatory approval and commercialize it as a CDx for Janssen's amivantamab. 

Thermo Fisher has also applied to the Japanese Ministry of Health, Labor, and Welfare to expand the use of the Oncomine Dx Target test in Japan.

Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

Aug
25

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.